Finally, the distribution of the mutations among primary and metastatic tissues demonstrated no statistically significant differences in the proportions of EGFR mutations detected in primary lung adenocarcinomas (51/452 mutations, 11.3%) and those found in metastatic samples (8/63 mutations, 12.7%). This evidence concerns the gene EGFR and lung adenocarcinoma.